Efficacy of neoadjuvant strategies with gemcitabine and other chemotherapy in resectable non-small cell lung cancer: a combined modality approach.
Radical surgery remains the cornerstone of treatment for early non-small cell lung cancer, but disappointing long-term results suggest that an alternative strategy is needed (ie, a combined modality approach). Data from randomized clinical trials testing different postoperative strategies have failed to show survival benefits. Promising data with preoperative chemotherapy using platinum-based regimens in early non-small cell lung cancer make this approach a priority for study in ongoing clinical trials. Current trials investigating the efficacy of neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer, including the Chemotherapy for Early Stages Trial comparing preoperative gemcitabine/cisplatin plus surgery versus surgery alone, will eventually include more than 3,000 total patients.
Scagliotti
Giorgio V
GV
Department of Clinical & Biological Sciences, Thoracic Oncology Unit, S. Luigi Hospital, University of Torino, Orbassano, Italy.
Novello
Silvia
S
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery*; D002945:Cisplatin / Q000627:therapeutic use; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000601:surgery*; D020360:Neoadjuvant Therapy; D016032:Randomized Controlled Trials as Topic; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine